U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07286604) titled 'Ivermectin Repurposed for the Treatment of PKDL' on Dec. 03.
Brief Summary: Background (brief):
1. Burden: Post-Kala-Azar Dermal Leishmaniasis (PKDL) commonly follows visceral leishmaniasis (VL) caused by Leishmania donovani. It is characterized by skin lesions in which parasites can be identified, in a patient who is otherwise fully recovered from VL or exposed to L. donovani (LD) infection. It occurs in the Indian subcontinent (mainly India and Bangladesh) as well as in Africa (mainly Sudan). It is now established that PKDL patients play an important role in transmission of LD parasite where chronic PKDL patients have been implic...